Nothing unexpected here. Of course SNTA has to raise some cash, and they have to do it before the Enchant-1 breast cancer data is released. Management was remiss in not doing it before the update of Galaxy-1. The people who were talking about how the Galaxy-1 update was great if they just omitted the two "outlier" Eastern European enrollment sites should have realized that things weren't so clean and easy when SNTA increased the size of Galaxy-2. After we get an idea of the size and price of the new share offering, and after the stock reacts, I will consider buying back some of the shares I sold at $5.13. If the Enchant-1 data looks good and stock rises significantly, then I will sell some again.